AgomAb Therapeutics (NASDAQ:AGMB) Sees Strong Trading Volume – What’s Next?

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) saw strong trading volume on Friday . Approximately 265,532 shares were traded during trading, an increase of 103% from the previous session’s volume of 131,018 shares.The stock last traded at $13.8680 and had previously closed at $13.50.

Wall Street Analyst Weigh In

A number of analysts recently commented on AGMB shares. HC Wainwright began coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 price target on the stock. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

AgomAb Therapeutics Stock Performance

The stock’s 50 day moving average is $12.18. The company has a current ratio of 6.52, a quick ratio of 6.52 and a debt-to-equity ratio of 0.01.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that AgomAb Therapeutics NV will post -1.84 EPS for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.